MAP Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Still shy of its first birthday, MAP Pharmaceuticals Inc. has a lead product for pediatric asthma about to enter Phase II trials, a pulmonary delivery platform that has the potential to create highly-differentiated respiratory and systemic therapeutics, and $31.5 million in backing from committed, deep-pocketed investors.